A growing need for cell therapy is anticipated to lead to an expansion of the global market for cell processing. For many illnesses like cancer, autoimmune disease, and neurological disease, cell therapy is the sole curative option. A million or more stem cell transplants were carried out worldwide in 2012, according to the Worldwide Network for Blood and Marrow Transplantation (WBMT). Another important element influencing the size of the cell processing industry is ongoing research and development for novel approaches for cell isolation, concentration, and preservation. Researchers have created a new magnetic ratcheting mechanism to separate and organize cells contained in fluid samples based on their tiny biochemical distinctions, according to a University of California, Los Angeles (UCLA) research paper from 2016. The system can differentiate therapeutic cells from non-therapeutic cells, perform simple, rapid automation of cell analysis, and sort cells more rapidly and precisely. Due to the rising number of cell banks in countries like China, India, Singapore, and Malaysia, the Asia Pacific cell processing market's revenue is anticipated to experience considerable increase over the forecast period.
According to Coherent Market Insights, in 2022, the market for Cell Processing was estimated to be worth USD 4.77 billion. From 2023 to 2030, it is anticipated that the market will expand at a CAGR of 16.5%.
Major Players in the Cell Processing Industry:
GE Healthcare
The firm was founded in 1892 and is based in Boston, Massachusetts, United States. A global leader in financial services and technology, General Electric Company. The company offers a range of goods and services, from industrial goods to medical imaging, corporate and consumer financing, water treatment, and home appliances. To increase the global availability of HA gas turbine services, GE will expand the scope of its Singapore repair centre in June 2023.
Becton, Dickinson and Company
The company was established in 1897 and has its headquarters in New Jersey, U.S. The business produces and markets reagents, instrument systems, and medical equipment. BD receives FDA 510(k) clearance in March 2023 for the first-ever high-throughput diagnostic test for infectious vaginitis. BD will launch a High-Throughput Single-Cell Multiomics Platform in February 2023 to broaden the scope of scientific discovery.
